Following on from our review of trends in the current pharmaceutical R&D pipeline, published in early February 2016, this supplement takes a look at the industry’s success stories of 2015 – the drugs which were launched on to the market for the first time during the year. Our survey focuses exclusively on new active substances (NASs): new chemical or biological entities where the active ingredient had received no prior approval for human use. As such, this list represents a subset of all the first launches which Citeline reported during 2015, excluding the 68 new drug launches with reformulated or non-NAS moieties, or biosimilars.
This year, our 2016 Pharma R&D Report showed the cast list of drugs in pharma R&D to be growing at an ever increasing rate. But is pharma’s equivalent of the Hollywood hit factory creating enough bona fide new stars? And of those who did make it, which are likely to be nominated for Best Newcomer awards? Is the industry basking in the golden spotlight of success, or flailing in a self-deluded bubble? Roll opening titles…
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: